Dakota Wealth Management Cuts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Dakota Wealth Management trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 38.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,957 shares of the company’s stock after selling 6,806 shares during the quarter. Dakota Wealth Management’s holdings in AstraZeneca were worth $718,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. McClarren Financial Advisors Inc. raised its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca during the 3rd quarter valued at $28,000. Ashton Thomas Securities LLC purchased a new position in AstraZeneca in the 3rd quarter worth $45,000. Hollencrest Capital Management lifted its stake in AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after purchasing an additional 192 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after buying an additional 707 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 0.7 %

AZN opened at $69.06 on Friday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a 50 day simple moving average of $66.33 and a two-hundred day simple moving average of $74.24. The firm has a market capitalization of $214.16 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.87 earnings per share. Analysts predict that AstraZeneca PLC will post 4.12 EPS for the current year.

Analysts Set New Price Targets

AZN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.